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Introduction
AA amyloidosis is the most severe complication of heredi-
tary autoinflammatory diseases. In TRAPS it has been
reported to occur in approximately 25% of patients in the
absence of an effective treatment. However, susceptibility
to AA is difficult to predict. Identification of key risk
factors affecting the development of AA would improve
the clinical management of TRAPS patients, by allowing a
more tailored treatment approach.
Objectives
To evaluate the relative contribution of clinical and
genetic factors to the risk of AA amyloidosis in TRAPS.
Methods
Clinical data were obtained from the EUROFEVER/
EUROTRAPS web-based registry. Inclusion criteria for
this study were: age ≥ 18 years at last follow-up, identifica-
tion of a TNFRSF1A mutation and written informed
consent. DNA was available for patients recruited into the
EUROTRAPS research project and SAA1 was genotyped
by direct sequencing of exon 3.
Results
104 patients (51 males, 49%) with TRAPS (39 different
mutations) were included in the study. Median age was
41 years (range 18-88), median age at TRAPS onset was
6 years (range 0.5-63), and median age at diagnosis was
37 years (10-81). 21 patients had AA amyloidosis, with a
median age at AA onset of 38 years (range 18-76). Family
history for AA amyloidosis was observed in 33 patients
(32%). SAA1 genotype was established in 89/104 patients
and 31 (35%) were homozygous for the SAA1.1 allele.
77 patients (74%) had a clearly pathogenic TNFRSF1A
variant. 27 had either P46L or R92Q.
At univariate analysis, family history for amyloidosis,
SAA1.1 homozygosity, disease course, age at TRAPS onset
and the type of mutation were significantly associated with
AA amyloidosis. At multivariate analysis homozygosity for
SAA1.1 and age at TRAPS onset independently predicted
development of renal amyloidosis. SAA1.1/1.1 genotype
was the variable with the strongest influence on AA devel-
opment, with a 5.3 fold increased risk whereas older age at
TRAPS onset was associated with a reduced risk of AA
amyloidosis. Survival according to SAA1 genotype
(SAA1.1/SAA1.1 versus all other genotypes) was estimated
by Kaplan-Meier analysis. Median amyloid free survival
from birth was 47 years vs. not reached (p=0.01).
Conclusion
Homozygosity for the SAA1.1 allele is the strongest
predictor of AA risk in TRAPS. This result is extremely
relevant for the clinical management of TRAPS patients
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